Natera announces CRC trial collaboration: Natera stock after-hours at EUR 353.50
Published on 10/13/2026 at 22:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrial plans and session figures
- Natera announced a colorectal cancer collaboration on October 13, 2026, supporting enrollment in a Phase 2a trial.
- Natera stock traded after-hours at EUR 353.50 at 10:49 p.m. CEST at Lang & Schwarz on October 13, 2026.
- The Lang & Schwarz bid was EUR 352.80 and the ask was EUR 354.20.
- The next Xetra session is scheduled for October 14, 2026.
On October 13, 2026, Natera announced a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a trial of TTX-MC138 in colorectal cancer, according to Business Wire. Separately, Natera stock traded after-hours at Lang & Schwarz at EUR 353.50 at 10:49 p.m. CEST on October 13, 2026.
Daily balance
Lang & Schwarz showed a bid of EUR 352.80 and an ask of EUR 354.20. Nasdaq quote data listed Natera's October 13 session range at USD 383.01 to USD 397.53, with volume of 1,117,911 shares.
The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Natera stock.
Trial collaboration details
Patients in the trial will be eligible if they have completed curative-intent therapy, remain positive for molecular residual disease detected by Natera's Signatera test and have no radiographic evidence of disease. The study is being conducted by Quantum Leap Healthcare Collaborative within its PRE-I-SPY program, and TTX-MC138 is designed to inhibit microRNA-10b.
Tomorrow, the next Xetra session is scheduled for October 14, 2026.
Market context: Market report Nasdaq Composite.
